Literature DB >> 23389763

JAK2 V617F mutation positive primary myelofibrosis with concomitant t(9;11;22)(q34;p15;q11.2) but no BCR/ABL fusion.

Wing-Yan Au, Thomas S K Wan, Edmond S K Ma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23389763     DOI： 10.1007/s12185-013-1287-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

1.  Translocation (15;17)(q22;q21) not associated with acute promyelocytic leukemia and negative for PML/RARa rearrangement.

Authors:  E S Kwan Ma; T S Kong Wan; Y Lam Kwong; L C Chan
Journal:  Haematologica       Date:  2000-07       Impact factor: 9.941

2.  Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.

Authors:  Yeo-Kyeoung Kim; Myung-Geun Shin; Hye-Ran Kim; Deok-Hwan Yang; Sang-Hee Cho; Je-Jung Lee; Ik-Joo Chung; Dong-Wook Ryang; Hyeoung-Joon Kim
Journal:  Leuk Res       Date:  2007-12-04       Impact factor: 3.156

3.  Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.

Authors:  K Hussein; O Bock; K Theophile; A Seegers; H Arps; O Basten; K-H Grips; J Franz-Werner; G Büsche; H Kreipe
Journal:  Leukemia       Date:  2007-11-01       Impact factor: 11.528

4.  JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.

Authors:  N Cambier; A Renneville; T Cazaentre; V Soenen; C Cossement; S Giraudier; N Grardel; J-L Laï; C Rose; C Preudhomme
Journal:  Leukemia       Date:  2008-02-21       Impact factor: 11.528

5.  JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.

Authors:  Leonardo Campiotti; Lorena Appio; Francesco Solbiati; Walter Ageno; Achille Venco
Journal:  Leuk Res       Date:  2009-07-09       Impact factor: 3.156

6.  Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.

Authors:  Laurent Jallades; Sandrine Hayette; Isabelle Tigaud; Anna Johnston; Bertrand Coiffier; Jean-Pierre Magaud; Martine Ffrench
Journal:  Leuk Res       Date:  2008-04-29       Impact factor: 3.156

7.  The double jeopardy of clustered measurement and cluster randomisation.

Authors:  Michael S Kramer; Richard M Martin; Jonathan A C Sterne; Stanley Shapiro; Mourad Dahhou; Robert W Platt
Journal:  BMJ       Date:  2009-08-21
  7 in total
  1 in total

1.  CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma.

Authors:  Tengyue Zhang; Kelong Ma; Jin Huang; Shitang Wang; Yabei Liu; Gaofei Fan; Miao Liu; Guangshan Yang; Cheng Wang; Pingsheng Fan
Journal:  Oncotarget       Date:  2017-10-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.